treatment strategies for patients with dlbcl who relapse after car-t therapy
Published 1 year ago • 123 plays • Length 5:24Download video MP4
Download video MP3
Similar videos
-
2:14
treatment options for patients with dlbcl who relapse after car-t therapy
-
4:29
improving survival outcomes and optimizing car-t therapy in patients with dlbcl
-
1:55
treatment options for dlbcl patients who relapse after car-t cell therapy
-
3:23
phase i study of cd22 car-t therapy in patients with lbcl who have relapsed after cd19 car-t therapy
-
0:32
enhancing outcomes of patients with dlbcl treated with car t-cell therapy
-
3:28
management of relapse after car-t
-
6:54
the future of car-t therapy in the management of dlbcl
-
1:33
management of relapse after car-t in patients with b-cell lymphoma
-
3:55
managing relapse post-car-t therapy in dlbcl & the need to change clinical trial inclusion criteria
-
1:39
managing early & late relapse after first-line therapy for dlbcl
-
4:14
choosing the right car-t therapy for r/r dlbcl
-
2:05
strategies to implement car-t in dlbcl
-
1:55
exploring first-line car-t therapy for the treatment of dlbcl
-
1:20
managing relapse after car-t therapy in all
-
3:52
updates on the use of car-t therapy for the treatment of dlbcl in the second-line setting
-
1:04
bispecifics & car-t therapy in dlbcl: sequencing and selecting between these agents
-
1:06
car-t cell therapy: current applications and how to improve treatment strategies in the future
-
3:23
real-world outcomes of patients with transformed r/r dlbcl treated with cd19 car-t therapy
-
7:40
immunotherapy for aml and all: checkpoint inhibitors & car t-cells for b-cell all